Tribenoside
 | |
| Clinical data | |
|---|---|
| Other names | (3R,4R,5R)-4-(Benzyloxy)-5-[1,2-bis(benzyloxy)ethyl]-2-ethoxyoxolan-3-ol |
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.030.612 |
| Chemical and physical data | |
| Formula | C29H34O6 |
| Molar mass | 478.585 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Tribenoside (Glyvenol) is a vasoprotective drug used to treat hemorrhoids.[1] It has mild anti-inflammatory, analgesic, and wound healing properties.[2] Tribenoside stimulates laminin α5 production and laminin-332 deposition to help repair the basement membrane during the wound healing process.[3] It is a mixture of the α- and β-anomers.[citation needed]
Tribenoside has been shown to induce drug hypersensitivity syndrome in association with CMV reactivation.[4]
References
[edit]- ^ Lorenc Z, Gökçe Ö (2016). "Tribenoside and lidocaine in the local treatment of hemorrhoids: an overview of clinical evidence". Eur Rev Med Pharmacol Sci. 20 (12): 2742–51. PMID 27383331.
- ^ Jaques R (1977). "The pharmacological activity of tribenoside". Pharmacology. 15 (5): 445–60. doi:10.1159/000136721. PMID 578928.
- ^ Kikkawa Y, Takaki S, Matsuda Y, Okabe K, Taniguchi M, Oomachi K, Samejima T, Katagiri F, Hozumi K, Nomizu M (2010). "The influence of Tribenoside on expression and deposition of epidermal laminins in HaCaT cells". Biol Pharm Bull. 33 (2): 307–10. doi:10.1248/bpb.33.307. PMID 20118558.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Hashizume H, Takigawa M (2005). "Drug-induced hypersensitivity syndrome associated with cytomegalovirus reactivation: immunological characterization of pathogenic T cells". Acta Derm. Venereol. 85 (1): 47–50. doi:10.1080/00015550410024094. PMID 15848991.
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |